| Record ID | harvard_bibliographic_metadata/ab.bib.13.20150123.full.mrc:582035818:1370 |
| Source | harvard_bibliographic_metadata |
| Download Link | /show-records/harvard_bibliographic_metadata/ab.bib.13.20150123.full.mrc:582035818:1370?format=raw |
LEADER: 01370cam a2200313 a 4500
001 013532167-0
005 20130921022703.0
008 130108s2013 fr a b 000 0 eng
010 $a 2012949364
020 $a9782817803357 (alk. paper)
020 $a9782817803364 (ebook)
035 0 $aocn826803727
040 $aDNLM$cDNLM
041 1 $aeng$hfre
042 $apcc
060 00 $a2013 A-502
060 10 $aQV 241
130 1 $aBiosimilaires.$lEnglish.
245 10 $aBiosimilars :$ba new generation of biologics /$cJean-Louis Prugnaud, Jean-Hugues Trouvin, editors.
260 $aParis :$bSpringer,$cc2013.
300 $axvii, 87 p. :$bill. ;$c24 cm.
504 $aIncludes bibliographical references.
505 00 $tBiologicals' Characteristics / K. Ho and J.-H. Trouvin --$tFrom the Biosimilar Concept to the Marketing Authorisation / M. Pavlovic and J.-L. Prugnaud --$tImmunogenicity / J.-L. Prugnaud --$tSubstitution and Interchangeability / J.-L. Prugnaud --$tG-CSFs: Onco-Hematologist's Point of View / D. Kamioner --$tThe Oncologist's Point of View / C. Chouaïd --$tBiosimilars: Challenges Raised by Biosimilars: Who is Responsible for Cost and Risk Management? / F. Megerlin.
650 12 $aBiosimilar Pharmaceuticals.
650 0 $aBiologicals.
700 1 $aPrugnaud, Jean-Louis.
700 1 $aTrouvin, Jean-Hugues.
988 $a20130108
906 $0OCLC